BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding 'RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended April 2026'.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaxi Pharmaceuticals has submitted a mandatory RTA report as per SEBI Circular dated 30th January, 2026. The filing covers the period ended April 2026 and reports NIL (zero) requests received, processed, approved, and rejected for re-lodgement of physical share transfers. This special window was provided by SEBI to allow shareholders holding physical shares to re-lodge their share transfer requests. The NIL figures indicate no shareholders availed this facility during April 2026, suggesting most of the company's shareholding is already in dematerialized form.
This filing has no direct impact on shareholders as it reflects zero activity. The NIL requests suggest the company's shareholder base is largely dematerialized, which is positive from an operational standpoint as physical share processing carries higher risks and costs.